.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its leading biopharma selection for 2025 as well as measured another 9 titles in the room as overweight. The expenditure banking company mentioned in a details that it remains to feel “diabesity is readied to end up being.